Ameriflight and Epic Flight Academy Sign Cadet Pathway Program Press Release from BusinessWire.com has been published today, Marcin Frąckiewicz, .
DALLAS–(BUSINESS WIRE)–Ameriflight and Epic Flight Academy have entered into a cadet pathway program that will allow pilots to go from no licenses or aviation experience to piloting aircraft for a large airline in just five years. Participants will begin earning competitive pay six months in and will leave the program debt-free, a rare advantage in the aviation industry.
In the program, participants will receive 10 months of primary training as a student and 15 months of advanced training as a Certified Flight Instructor while accumulating 1200 hours of flight experience at Epic Flight Academy. Upon completion, they will come directly to Ameriflight where they will work as a captain for three years. During this time, they will advance within Ameriflight and have the opportunity to be placed in one of Ameriflight’s flow through or gateway programs with large airlines such as UPS Airlines, Omni Air, Allegiant Air, and Frontier Airlines. The cadet program from start to finish can be completed in as little as five years, compared to a university program and building experience through a regional airline which can take close to 11 years along with tens of thousands of dollars in cost.
The first group of the program’s cadets will soon be transferring to Ameriflight. Epic will begin enrollment of new individuals in the first quarter of 2018.
“We are excited about expanding the cadet program with Ameriflight,” says Danny Perna, CEO of Epic. “The program not only helps students overcome financial barriers to reach their aviation goals, but it also creates a streamlined career pathway that enhances training and safety.”
“These programs are a major contributor to Ameriflight’s ability to hire qualified pilots to fulfill current needs and meet the demands of the growing ecommerce market,” says Brian Randow, CEO of Ameriflight.
About Ameriflight: Ameriflight was founded in 1968 and has grown from a small air charter and cargo service carrier to an international operator and the nation’s largest 135 cargo airline. Ameriflight is headquartered in Dallas, TX and has more than 500 employees, including over 100 pilots and 100 aircraft. Ameriflight provides feeder services for overnight express carriers such as UPS, FedEx, and DHL. The company can be found on the web at ameriflight.com and on Facebook, Instagram, and Twitter at @Ameriflight.
About Epic Flight Academy: Since 1999, Epic Flight Academy has been successfully training airline pilots. Epic Flight Academy, a FAA 141 pilot school, operates in New Smyrna Beach, Florida and annually trains 200 pilots for 77 different countries, providing pilots for more than 33 airlines worldwide. The company can be found on the web at epicflightacademy.com and on Facebook, Instagram, and LinkedIn at @EpicFlightAcademy.
Chevron Announces Major Oil Discovery in Deepwater Gulf of Mexico Press Release from BusinessWire.com has been published today, Marcin Frąckiewicz, .
SAN RAMON, Calif.–(BUSINESS WIRE)–Chevron Corporation (NYSE:CVX) today announced a significant oil discovery at the Ballymore prospect in the deepwater U.S. Gulf of Mexico.
Ballymore is located in the Mississippi Canyon area of the U.S. Gulf of Mexico, approximately three miles from Chevron’s Blind Faith platform, in water depth of 6,536 feet. The initial Ballymore well reached total measured depth of 29,194 feet and encountered more than 670 feet net oil pay with excellent reservoir and fluid characteristics. A sidetrack well is currently being drilled to further assess the discovery and begin to define development options.
“The Gulf of Mexico deepwater is an integral part of our company’s long-term strategy,” said Jeff Shellebarger, President of Chevron North America Exploration and Production. “This discovery is an important addition to our portfolio, especially with its combination of size, quality and proximity to existing infrastructure.”
Chevron subsidiary Chevron U.S.A. Inc. is the operator with a 60 percent working interest in the Ballymore prospect. The co-owner is TOTAL E&P USA Inc. (40 percent).
Chevron Corporation is one of the world’s leading integrated energy companies. Through its subsidiaries that conduct business worldwide, the company is involved in virtually every facet of the energy industry. Chevron explores for, produces and transports crude oil and natural gas; refines, markets and distributes transportation fuels and lubricants; manufactures and sells petrochemicals and additives; generates power; and develops and deploys technologies that enhance business value in every aspect of the company’s operations. Chevron is based in San Ramon, Calif. More information about Chevron is available at www.chevron.com.
CAUTIONARY STATEMENTS RELEVANT TO FORWARD-LOOKING INFORMATION FOR THE PURPOSE OF “SAFE HARBOR” PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains forward-looking statements relating to Chevron’s operations that are based on management’s current expectations, estimates and projections about the petroleum, chemicals and other energy-related industries. Words or phrases such as “anticipates,” “expects,” “intends,” “plans,” “targets,” “forecasts,” “projects,” “believes,” “seeks,” “schedules,” “estimates,” “positions,” “pursues,” “may,” “could,” “should,” “budgets,” “outlook,” “trends,” ”guidance,” “focus,” “on schedule,” “on track,” “goals,” “objectives,” “strategies,” “opportunities,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, many of which are beyond the company’s control and are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Chevron undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Among the important factors that could cause actual results to differ materially from those in the forward-looking statements are: changing crude oil and natural gas prices; changing refining, marketing and chemicals margins; the company’s ability to realize anticipated cost savings and expenditure reductions; actions of competitors or regulators; timing of exploration expenses; timing of crude oil liftings; the competitiveness of alternate-energy sources or product substitutes; technological developments; the results of operations and financial condition of the company’s suppliers, vendors, partners and equity affiliates, particularly during extended periods of low prices for crude oil and natural gas; the inability or failure of the company’s joint-venture partners to fund their share of operations and development activities; the potential failure to achieve expected net production from existing and future crude oil and natural gas development projects; potential delays in the development, construction or start-up of planned projects; the potential disruption or interruption of the company’s operations due to war, accidents, political events, civil unrest, severe weather, cyber threats and terrorist acts, crude oil production quotas or other actions that might be imposed by the Organization of Petroleum Exporting Countries, or other natural or human causes beyond its control; changing economic, regulatory and political environments in the various countries in which the company operates; general domestic and international economic and political conditions; the potential liability for remedial actions or assessments under existing or future environmental regulations and litigation; significant operational, investment or product changes required by existing or future environmental statutes and regulations, including international agreements and national or regional legislation and regulatory measures to limit or reduce greenhouse gas emissions; the potential liability resulting from other pending or future litigation; the company’s future acquisition or disposition of assets or shares or the delay or failure of such transactions to close based on required closing conditions; the potential for gains and losses from asset dispositions or impairments; government-mandated sales, divestitures, recapitalizations, industry-specific taxes, changes in fiscal terms or restrictions on scope of company operations; foreign currency movements compared with the U.S. dollar; material reductions in corporate liquidity and access to debt markets; the impact of the 2017 U.S. tax legislation on the company’s future results; the effects of changed accounting rules under generally accepted accounting principles promulgated by rule-setting bodies; the company’s ability to identify and mitigate the risks and hazards inherent in operating in the global energy industry; and the factors set forth under the heading “Risk Factors” on pages 20 through 22 of the company’s 2016 Annual Report on Form 10-K. Other unpredictable or unknown factors not discussed in this press release could also have material adverse effects on forward-looking statements.
Richard T. Yung, M.D., F.A.C.S., is recognized by Continental Who's Who Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .
SCARSDALE, N.Y., Jan. 30, 2018 /PRNewswire/ — Richard T. Yung, M.D., F.A.C.S., is recognized by Continental Who’s Who as a Pinnacle Lifetime Member in the field of Healthcare in recognition of his role as an Otolaryngologist and Facial Plastic Surgeon with ENT & Allergy Associates.
Established in 1998, ENT & Allergy Associates has grown to be home to nearly 170 physicians practicing in over forty locations across the New York tri-state area. Offering a wide array of services to their clients, ENT & Allergy is dedicated to the health and wellness of their patients. Devoted to offering quality customer service, the clinic specializes in ear, nose and throat, swallowing, ear and dizziness, sleep services, advanced sinus/skull base and more.
Amassing over twenty three years of experience in the healthcare field, Dr. Yung is a revered otolaryngologist. Throughout his career, Dr. Yung has attained expertise within the areas of adult and pediatric ear, nose and throat health, snoring and sleep disorders, as well as various facial and reconstructive plastic surgeries. A renowned scholar, Dr. Yung is the author of “Botolinum Assisted Browlift.”
To further his professional development, Dr. Yung is an affiliate of several organizations including the American Medical Association, American Academy of Otolaryngology-Head and Neck Surgery and the American Academy of Facial Plastic and Reconstructive Surgery. Board Certified by the American Board of Otolaryngology, Dr. Yung is an esteemed expert within the field.
In recognition of his professional accolades, Dr. Yung was the recipient of the 1995 Norman E. Stoller Award for the best surgical resident at Beth Israel Medical Center and later earned the 1999 New York Medical College Resident Teaching Award. Later, Dr. Yung was the recipient of the John Orlando Roe Award for Best Clinical Research in Facial Plastic Surgery by a Fellow. Most recently, Dr. Yung was honored with the 2016 Top Doctor Award.
Throughout the course of his education and training, Dr. Yung attained his Medical degree from the Columbia University College of Physicians and Surgeons following his undergraduate degree in Chemistry from Johns Hopkins University. Thereafter, Dr. Yung completed his otolaryngology residency at The New York Eye & Ear Infirmary, followed by a Facial Plastic and Reconstructive Surgery Fellowship at Buckhead Facial Plastic Surgery in Atlanta, Georgia.
Dr. Yung dedicates this recognition in memory of Dr. Chris Lynstrom and Dr. Lawrence Dyer.
Allegiant Announces Donation To Las Vegas Victims' Fund Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .
LAS VEGAS, Jan. 30, 2018 /PRNewswire/ — Las Vegas-based Allegiant (NASDAQ: ALGT) today announces a donation of $362,358 to the Las Vegas Victims’ Fund, supporting those impacted by the tragic events of October 1. Allegiant team members from across the country raised more than $181,000 by donating hours of paid leave time. The company’s leadership team matched employees’ contributions personally.
Clark County Commission Chairman Steve Sisolak meets Allegiant team members at the company’s headquarters in Las Vegas. Sisolak accepted a company donation on behalf of the Las Vegas Victims’ Fund.
“Las Vegas is our home – and from the moment this tragic event unfolded, it was important to our team to pull together to support those affected in any way possible, and stand strong with the community we all love,” said Maury Gallagher, Allegiant chairman and CEO. “We are proud to stand shoulder-to-shoulder with so many others who have given deeply of their time and resources to aid with recovery, and hope our contribution will encourage additional support.”
Allegiant® Las Vegas-based Allegiant (NASDAQ: ALGT) is focused on linking travelers in small cities to world-class leisure destinations. The airline offers industry-low fares on an all-jet fleet while also offering other travel-related products such as hotel rooms and rental cars. All can be purchased only through the company website, Allegiant.com. Beginning with one aircraft and one route in 1999, the company has grown to more than 85 aircraft and 350 routes across the country with base airfares less than half the cost of the average domestic roundtrip ticket. For downloadable press kit, including photos, visit: http://gofly.us/iiFa303wrtF.
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .
LA JOLLA, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) has been accepted for presentation at the American Academy of Neurology (AAN) 70th Annual Meeting to be held April 21-27, 2018 in Los Angeles, California. The presentation entitled “Ibudilast – Phosphodiesterase Type 4 Inhibitor – Bi-Modal Therapy with Riluzole in Early [Not Requiring Non-Invasive Ventilation (NIV )] Cohort (EC) and Advanced [Requiring NIV](ANC) Amyotrophic Lateral Sclerosis (ALS) Patients – Single-Center Adaptive Design Six-Month Double-Blind (DB) – Placebo-Controlled Phase 1b/2a Epoch Followed by Six-Month Open Label Extension (OLE) Epoch, Washout (WO) and Post-Washout Epoch (PWO) – Final Report and Future Directions“ will be available for review throughout the afternoon on April 27th and presented by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute.Presentation details are as follows:Date and Time: Friday, April 27, 2018, 11:30 am – 5:30 pmSession: Poster Session P6Location: Los Angeles Convention Center, 1201 South Figueroa Street, Los Angeles, CA 90015About the ALS TrialMediciNova, in collaboration with Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute, evaluated 60mg of MN-166 (ibudilast) per day in early and advanced stage ALS patients. All subjects in the study received 100mg of riluzole per day. This trial was a randomized, double-blind, placebo-controlled study which included a six-month treatment period followed by a six-month open-label extension. The primary endpoint was safety and tolerability and the study also evaluated several efficacy endpoints including functional activity (ALSFRS-R). Data analyzed from the 51 early ALS subjects (the intent-to-treat/ITT population) was presented at the 28th International Symposium on ALS/MND in Boston, MA in December 2017. There was a higher rate of responders on the ALSFRS-R total score, MMT (manual muscle testing) and ALSAQ-5 score (subjective quality-of-life questionnaire) in the MN-166 (ibudilast) group compared to the placebo group. This was the first study of MN-166 (ibudilast) in ALS and the study provides the necessary clinical data for powering assumptions for the next study of MN-166 (ibudilast) in ALS.About ALSAmyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The nerves lose the ability to trigger specific muscles, which causes the muscles to become weak. As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed. Life expectancy of an ALS patient is usually 2-5 years. According to the ALS Association, there are approximately 20,000 ALS patients in the U.S. and approximately 6,000 people in the U.S. are diagnosed with ALS each year.About MN-166 (ibudilast)MN-166 (ibudilast) has been marketed in Japan and Korea since 1989 to treat post-stroke complications and bronchial asthma. MediciNova is developing MN-166 for progressive multiple sclerosis (MS) and other neurological conditions such as ALS and substance abuse/addiction. MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. It attenuates activated glia cells, which play a major role in certain neurological conditions. Ibudilast’s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results and provide the rationale for its therapeutic utility in neurodegenerative diseases (e.g., progressive MS and ALS), substance abuse/addiction and chronic neuropathic pain. MediciNova has a portfolio of patents which cover the use of MN-166 (ibudilast) to treat various diseases including progressive MS, ALS, and drug addiction.About MediciNovaMediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2016 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.INVESTOR CONTACT: Geoff O’Brien Vice President MediciNova, Inc. email@example.com
National Research Corporation to Broadcast its 2017 Fourth Quarter and Year-End Conference Call Live on the Internet Press Release from GlobeNewsWire has been published today, Karol Rutkowski, .
Lincoln, Nebraska, Jan. 30, 2018 (GLOBE NEWSWIRE) — National Research Corporation (NASDAQ:NRCIA) (NASDAQ:NRCIB) today announced that it will provide an online web simulcast of its 2017 fourth quarter and year-end conference call on Wednesday, February 14, 2018. The Company’s results for the 2017 fourth quarter and year end will be released after the close of the market on Tuesday, February 13, 2018.A live audio webcast can be accessed at https://edge.media-server.com/m6/p/p59zya7p. The webcast will also be available for replay.National Research Corporation, headquartered in Lincoln, Nebraska, is a leading provider of performance measurement, improvement services, and governance education to the healthcare industry in the United States and Canada. Kevin R. Karas
Chief Financial Officer
Die Brightline Initiative gibt Forschungszusammenarbeit mit Dänemarks Technischer Universität, dem University of Tokyo Global Teamwork Lab und dem Massachusetts Institute of Technology Consortium for Engineering Program Excelle... Press Release from BusinessWire.com has been published today, Marcin Frąckiewicz, .
Die Brightline Initiative gibt Forschungszusammenarbeit mit Dänemarks Technischer Universität, dem University of Tokyo Global Teamwork Lab und dem Massachusetts Institute of Technology Consortium for Engineering Program Excellence bekannt
The Brightline Initiative kündigte heute Forschungszusammenarbeiten mit Dänemarks Technischer Universität Denmark (DTU), dem University of Tokyo Global Teamwork Lab (GTL) und dem Massachusetts Institute of Technology (MIT) Consortium for Engineering Program Excellence (CEPE) an. Die Initiative wird sich auf Spitzenforschung und Lösungen zur Strategieumsetzung konzentrieren.
Die Brightline™ Initiative wurde Anfang 2017 vom Project Management Institute (PMI), der Boston Consulting Group (BCG) und der Agile Alliance eingeleitet und hat sich zu einer nicht kommerziellen Koalition führender globaler Organisationen entwickelt mit dem Ziel, Führungskräfte dabei zu unterstützen, die kostspielige und unproduktive Lücke zwischen der Entwicklung und Umsetzung von Strategien zu schließen. Die Brightline Initiative konzentriert sich auf ihre drei Hauptaufgabenbereiche: Thought and Practice Leadership, Networking und Capability Building.
„Bei DTU sind wir äußerst erfreut über die Aufnahme in die Brightline Koalition. DTU hat sich zum Ziel gesetzt, konkrete soziale Vorteile zu schaffen. Dies ist der Grund, wenn wir neue wissenschaftliche Erkenntnisse und Technologien gewinnen, dass wir uns zudem auf ihre Umsetzung im Rahmen der tagtäglichen Abläufe von Organisationen und auf breiterer Ebene konzentrieren. Daher sind wir der Überzeugung, dass unsere Ziele und diejenigen von Brightline in hohem Maße übereinstimmen”, so Søren Salomo, Head of Department, DTU Management Engineering.
„Wir freuen uns bereits, unseren Beitrag zur Verbesserung der Strategieumsetzung, insbesondere durch unsere Forschungsarbeit im Hinblick auf eine bessere Steuerung der damit in Zusammenhang stehenden Risiken und Unwägbarkeiten bei technologieorientierten Organisationen leisten zu können”, erklärte Josef Oehmen, Associate Professor bei DTU.
„Die Zusammenarbeit mit der Brightline Initiative bietet eine einzigartige Gelegenheit für die Evaluierung der Schnittstelle zwischen Strategie-Entwicklung und -Planung auf der Grundlage pragmatischer operativer Aspekte, des organisatorischen Lernens und der Veränderungen. Wir freuen uns außerordentlich über die Gelegenheit, neue ausgeklügelte Forschungsmethoden zur Gewinnung originärer Einblicke in die Entscheidungsfindung zu entwickeln, um ihre bestmögliche Umsetzung und den künftigen Erfolg zu gewährleisten”, so Eric Rebentisch, Research Associate bei MIT.
Strategien befinden sich in stetigem Wandel, um ihre notwendige Anpassung zu gewährleisten.  In einer Welt mit unberechenbaren Störfällen müssen sich die Organisationen mit ihrem Ökosystem bei der Entwicklung und Umsetzung ihrer Strategie vertraut machen. Zusammenarbeit und Kommunikation, Wissen und Fähigkeiten sind die Eckpfeiler einer erfolgreichen Vorgehensweise.
Dr. Kazuo Hiekata, Associate Professor an der Universität Tokio, erklärte: „Das GTL Team entwickelt Methoden und Tools für ein System von Systemen zur Förderung der Kommunikation über Grenzen hinweg. Unser gemeinsames Handeln im Rahmen der Brightline Initiative wird sowohl exzellente Forschungsergebnisse als auch signifikante Auswirkungen auf die Gesellschaft nach sich ziehen, indem wir Führungskräfte und erfahrene Mitarbeiter mithilfe neuartiger Verfahrensweisen vernetzen.” Dr. Kenji Tanaka, Project Associate Professor, ergänzte: „Etablierte Branchen wie der Energiesektor sind notwendig, um aufgrund des Aufkommens neuer Technologien und Serviceleistungen einen signifikanten Wandel von bestehenden Verfahrensweisen einzuleiten. Die Strategie und Umsetzung für etablierte Unternehmen sollte die Entwicklung widerspiegeln.”
Dai Ike, GTL Research Coordinator und GPD Japan CEO, führte weiter aus: „Japanische Unternehmen streben nach fortgeschrittener Methodologie und grenzüberschreitenden Teams für die Durchführung komplexer und unterschiedlicher Projekte, die mit der Unternehmensstrategie direkt in Zusammenhang stehen. Gleichzeitig zögern jedoch Unternehmen noch immer, den neuen Geschäftsweg zu beschreiten bis andere Unternehmen erfolgreich bestehen können. Die GTL Erfolgsgeschichten sind genau diejenigen, die von Unternehmen angestrebt werden.”
Ricardo Vargas, Executive Director von Brightline, erklärte: „Die Zusammenarbeit mit DTU, GTL und MIT Forschungseinrichtungen stärkt die Brightline Mission der Schließung der Lücke zwischen Strategieplanung und -Umsetzung durch modernste Forschungsarbeit. Organisationen und Führungskräfte werden von Best-Practice-Methoden in ihrem Streben nach Strategieumsetzung in dieser Ära disruptiver Innovationen profitieren. DTU, GTL und die MIT Gruppen sorgen aufgrund ihrer Forschungsgebiete für einzigartige Perspektiven. Ihre Erfahrungen und ihr Hintergrundwissen zu Strategiefragen werden von außergewöhnlichem Nutzen für unser gemeinsames Streben nach erfolgreichem Strategie-Initiativenmanagement sein.”
Über die Brightline Initiative
Die Brightline™ Initiative ist eine nicht kommerzielle Koalition führender globaler Organisationen mit dem Ziel, Führungskräfte dabei zu unterstützen, die kostspielige und unproduktive Lücke zwischen der Entwicklung und Umsetzung von Strategien zu schließen. Brightline™ bietet Organisationen drei entscheidende Vorteile, die sie besser in die Lage versetzen sollen, ihre Strategieziele zu erreichen: Thought and Practice Leadership, Networking und Capability Building. Weitere Informationen finden Sie unter www.brightline.org.
Über Dänemarks Technische Universität
Dänemarks Technische Universität steht wissenschaftlich und fachübergreifend in den Bereichen Technik und Naturwissenschaften mit neuen Initiativen in einer Reihe anspruchsvoller ingenieurwissenschaftlicher Disziplinen, darunter nachhaltige Energietechnologie und Biowissenschaften, an vorderster Front. Website: dtu.dk
Über das University of Tokyo Global Teamwork Lab (GTL)
Das University of Tokyo Global Teamwork Lab (GTL) ist eine Partnerschaft zwischen Industrie und Universität für Forschungszwecke, Workshops und Schulungen zu grenzüberschreitendem Teamwork. Die GLT Forschungsarbeit konzentriert sich auf die zugrundeliegenden Mechanismen und Dynamiken der Leistungsfähigkeit unter komplexen Rahmenbedingungen. Website: gtl.k.u-tokyo.ac.jp
1] Economist Intelligence Unit (EIU), “Closing the Gap: Designing and Delivering a Strategy that Works”, 2017.
Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.
McCann Ranked No. 1 Globally by R3 in Winning New Business in 2017 Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .
NEW YORK, Jan. 30, 2018 /PRNewswire/ — According to R3, an independent global marketing consultancy, McCann Worldgroup led all agencies in 2017 in winning new business both globally and in the U.S. This analysis appeared in R3’s year-end “2017 Creative Agencies New Business League” table. Link: R3 New Business League
R3’s cumulative monthly global new business tables reflect the diverse marketing platforms that exist today. The major accounts won at the end of the year that appeared in the December R3 new business ranking included the global Chivas Regal brand and Pizza Hut in Latin America.
“Never before have we had so many different ways to reach consumers on behalf of our clients,” said Harris Diamond, Chairman and CEO of McCann Worldgroup. “It’s an exciting time to be in our business and I am proud of our creative, strategic and business leadership community for introducing marketers to effective solutions that can grow their businesses.”
McCann, which was named last month by Adweek as its 2017 U.S. Agency of the Year, consistently led the industry last year in creative recognition. This included recognition as the most awarded Cannes agency in North America, as the Most Effective Agency in the North American Effies, and as Agency of the Year at both the Clios and The One Show. McCann also was honored as the London International Awards’ Global and N.A. Agency of the Year as well as N.A. Network of the Year; as the International ANDY Awards’ Network and Agency of the Year; and as the ADC Annual Awards’ Network, Agency and Digital Agency of the Year.
About McCann Worldgroup McCann Worldgroup, part of the Interpublic Group (NYSE: IPG), is a leading global marketing services company with 24,000 employees in more than 100 countries, comprising McCann (advertising), MRM//McCann (digital marketing/relationship management), Momentum Worldwide (total brand experience), McCann Health (professional/dtc communications), CRAFT (global adaptation and production), UM (media management), Weber Shandwick (public relations), FutureBrand (consulting/design), and PMK-BNC (entertainment/brand/popular culture).
Alexander & Baldwin announces two financial leadership appointments Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .
HONOLULU, Jan. 30, 2018 /PRNewswire/ — Alexander & Baldwin, Inc. (NYSE: ALEX) (“A&B” or “Company”) announced Clayton Chun has been appointed as chief accounting officer and Kenneth Kan has been named as the company’s treasurer. Both Chun and Kan will continue to report to Jim Mead, A&B’s chief financial officer.
Chun also will continue to serve as A&B’s corporate controller, a position he assumed in 2015, and will be responsible for overseeing the company’s accounting operations, internal controls and financial reporting functions.
“We are excited to recognize Clayton for his increased responsibilities as he has taken over full management of the finance and accounting department, and guided improvements in process and additions to our technology platform. As a senior member of our team, his contributions will enable us to build and maintain a platform that will support our continued growth,” Mead said.
Prior to joining A&B, Chun was an audit senior manager at Deloitte & Touche, LLP in Los Angeles where he worked for 15 years. At Deloitte, Chun was responsible for managing complex integrated audit engagements, ranging from start-ups to multinational Fortune 500 companies, as well as other service functions which increased profitability, supported growth, and managed risk.
Chun is a certified public accountant (CPA). Raised in Hawaii, he earned a master’s degree in accounting from the University of Southern California and a bachelor’s degree in economics from Washington University in St. Louis, Missouri.
As treasurer, Kan has a senior role in managing corporate financing activities that include responsibilities in managing banking and capital market activities, corporate development and traditional treasury functions such as cash management.
“Kenny’s deep knowledge and experience add to our breadth of capabilities to develop financial options and manage our various investment activities. His appointment as treasurer recognizes his valuable continuing contributions,” Mead said.
Kan has extensive experience in finance, real estate and strategic planning. Prior to joining A&B, he most recently served with Outrigger Enterprises Group as corporate director, business planning and analysis working on the acquisitions, dispositions and financings for the company. Prior to that, he was chief financial officer for The Resort Group and also has served as vice president at Grove International Partners in New York and as a portfolio manager at Goldman Sachs Realty Japan Division in Tokyo.
Kan earned a bachelor’s degree in business administration, specializing in finance, from the University of Hawaii – Manoa and a master’s of business administration from the University of Chicago Booth School of Business.
United States Lime & Minerals Reports Fourth Quarter And Full Year 2017 Results And Declares Regular Quarterly Cash Dividend Press Release from PRNEWSWIRE has been published today, Maciej Heyman, .
DALLAS, Jan. 30, 2018 /PRNewswire/ — United States Lime & Minerals, Inc. (NASDAQ: USLM) today reported fourth quarter and full year 2017 results: Revenues in the fourth quarter 2017 were $35.2 million, compared to $34.2 million in the comparable prior year quarter, an increase of $1.1 million, or 3.1%. Revenues from the Company’s Lime and Limestone Operations in the fourth quarter 2017 increased $1.1 million, or 3.4%, to $34.7 million from $33.6 million in the comparable 2016 quarter, while revenues from its Natural Gas Interests decreased $65 thousand, or 10.8%, to $537 thousand from $602 thousand in the comparable prior year quarter. For the full year 2017, revenues were $144.8 million, compared to $139.3 million in 2016, an increase of $5.6 million, or 4.0%. Revenues from the Company’s Lime and Limestone Operations in 2017 increased $5.4 million, or 4.0%, to $142.6 million from $137.2 million in 2016. Revenues from its Natural Gas Interests increased $0.1 million, or 6.7%, to $2.2 million in 2017 from $2.1 million in 2016.
The increase in lime and limestone revenues in the fourth quarter 2017, as compared to the fourth quarter 2016, resulted primarily from increased demand from the Company’s oil and gas services and industrial customers, partially offset by decreased demand from its environmental and construction customers. The increase in the Company’s lime and limestone revenues in the full year 2017, compared to 2016, resulted primarily from increased sales volumes due to increased demand, principally from its oil and gas services and industrial customers, partially offset by reduced demand from its environmental customers. Prices realized for the Company’s lime and limestone products were slightly higher in each of the fourth quarter and full year 2017, compared to the comparable 2016 periods.
Production volumes from the Company’s Natural Gas Interests in the fourth quarter 2017 totaled 133 thousand MCF, sold at an average price of $4.03 per MCF, compared to 151 thousand MCF, sold at an average price of $3.98 per MCF, in the comparable 2016 quarter. Production volumes in the full year 2017 from Natural Gas Interests totaled 559 thousand MCF, sold at an average price of $3.99 per MCF, compared to 2016 when 625 thousand MCF was produced and sold at an average price of $3.35 per MCF. The Company’s average prices per MCF were higher in the 2017 periods, compared to the prior year periods, due to increases in market prices for natural gas and natural gas liquids.
The Company’s gross profit was $7.8 million in the fourth quarter 2017, compared to $7.4 million in the comparable 2016 quarter, an increase of $0.3 million, or 4.3%. Gross profit in 2017 was $34.4 million, an increase of $1.3 million, or 3.9%, from $33.1 million in 2016.
Included in gross profit in the fourth quarter and full year 2017 were $7.4 million and $33.7 million, respectively, from the Company’s Lime and Limestone Operations, compared to $7.4 million and $33.0 million, respectively, in the comparable 2016 periods. Gross profit for the Company’s Lime and Limestone Operations in the fourth quarter 2017 was essentially flat compared to the fourth quarter 2016, as increased revenues were largely offset by higher costs of operations. The increased gross profit in the full year 2017, compared to 2016, resulted primarily from the increased revenues in 2017 discussed above.
Gross profit from the Company’s Natural Gas Interests in the fourth quarter and full year 2017 were $318 thousand and $728 thousand, respectively, compared to gross profit of $79 thousand and $60 thousand in the fourth quarter and full year 2016, respectively. The increase in gross profit from the Company’s Natural Gas Interests in each of the fourth quarter and full year 2017, compared to the comparable 2016 periods, was primarily due to lower depletion and lease operating expenses and price increases in the 2017 periods, compared to the comparable 2016 periods.
Income tax benefit was $6.2 million and $2.2 million in the fourth quarter and full year 2017, compared to income tax expense of $1.2 million and $5.9 million in the fourth quarter and full year 2016, respectively. Income tax benefit in the fourth quarter and full year 2017 included a benefit of $7.4 million ($1.33 per share diluted in each of the fourth quarter and full year 2017) due to a reduction in the enacted federal income tax rates in the United States and the one-time impact of the lower rate on deferred tax liabilities, net.
The Company reported net income of $11.6 million ($2.07 per share diluted) in the fourth quarter 2017, compared to net income of $3.9 million ($0.70 per share diluted) in the fourth quarter 2016, an increase of $7.7 million, or 195.5%. The Company reported net income of $27.1 million for the full year 2017 ($4.86 per share diluted), compared to net income of $17.8 million ($3.19 per share diluted) in 2016, an increase of $9.4 million, or 52.9%. The increases in net income in the 2017 periods, compared to the 2016 periods, include the $7.4 million income tax benefit discussed above.
On November 17, 2017, the Company announced a 12-month extension of its repurchase program to repurchase up to the approximately $7.2 million of its common stock remaining under the program. No additional shares have been repurchased to date.
“Demand for our lime and limestone products in the fourth quarter and full year 2017 remained steady. In addition to the St. Clair replacement kiln project, we continue to seek innovative ways to enhance efficiencies at all of our facilities so we can compete in what remains a challenging pricing environment,” said Timothy W. Byrne, President and Chief Executive Officer.
Mr. Byrne added: “The Company is pleased to announce a $500 bonus for all non-executive employees. I am excited to invest a portion of the savings to the Company from the recently passed tax legislation directly back to our employees, which are our most important asset and the foundation of our continued success.”
The Company also announced today that the Board of Directors has declared a regular quarterly cash dividend of $0.135 (13.5 cents) per share on the Company’s common stock. This dividend is payable on March 16, 2018 to shareholders of record at the close of business on February 23, 2018.
United States Lime & Minerals, Inc., a NASDAQ-listed public company with headquarters in Dallas, Texas, is a manufacturer of lime and limestone products, supplying primarily the construction (including highway, road and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle and agriculture (including poultry and cattle feed producers) industries. The Company operates lime and limestone plants and distribution facilities in Arkansas, Colorado, Louisiana, Oklahoma and Texas through its wholly owned subsidiaries, Arkansas Lime Company, Colorado Lime Company, Texas Lime Company, U.S. Lime Company, U.S. Lime Company – Shreveport, U.S. Lime Company – St. Clair and U.S. Lime Company – Transportation. In addition, the Company, through its wholly owned subsidiary, U.S. Lime Company – O & G, LLC, has royalty and non-operating working interests pursuant to an oil and gas lease and a drillsite agreement on its Johnson County, Texas property, located in the Barnett Shale Formation.
Any statements contained in this news release that are not statements of historical fact are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The Company undertakes no obligation to publicly update or revise any forward-looking statements, and investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from expectations, including without limitation those risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission.